Rating: Medium

Researchers are studying characteristics that may increase breast cancer survivors’ therapy-related leukemia risk. They believe that there may be a genetic basis behind the development of therapy-related leukemia because approximately 1/5 of the women who developed leukemia had a mutation in BRCA, TP53, CHEK2 or PALB2. However, this study does not conclusively say that mutation carriers are at increased risk of developing therapy-related leukemia. More work, including a larger study as this study used a small number of patients, needs to be done in order to determine if there is a link between the two.